Table 1.
Comparison of the demographic and clinical characteristics between multiple sclerosis (MS) patients and non-MS controls in the merged dataset and in the validation group
| Datasets | Validation | |||||
|---|---|---|---|---|---|---|
| MS (n = 61) | Non-MS (31) | P | MS (n = 11) | Non-MS (n = 3) | P | |
| Age (years) | 44.87 ± 15.66 | 42.71 ± 12.00 | 0.466 | 29.73 ± 10.78 | 42.33 ± 11.85 | 0.195 |
| Sex (%) | ||||||
| Female | 37 (60.7%) | 19 (61.3%) | 0.953 | 8 (72.7%) | 2 (66.7%) | 0.837 |
| Male | 24 (39.3%) | 12 (38.7%) | 3 (27.3%) | 1 (33.3%) | ||
| Subtype (%) | ||||||
| RRMS | 32 (52.5%) | – | – | 8 (72.7%) | – | – |
| PPMS | 10 (16.4%) | – | 1 (9.1%) | – | ||
| SPMS | 19 (31.1%) | – | 2 (18.2%) | – | ||
| DMDs (%) | – | – | – | 3 (27.3%) | – | – |
| CSF testing | ||||||
| OB (%) | – | – | – | 1 (16.7%) | – | – |
| Antibody (%) (anti-AQP4, MOG, MBP) | 0 (0.0%) | |||||
In the validation group, six of the 11 MS patients underwent CSF OB testing, and only one patient found positive result. Nine of them measured related antibodies while all reported negative results